Table 4. Number of PSA tests, prostate cancer diagnoses and treatments and costs (in kEuro 2008) of a cohort of 100 000 men of all ages in the period 2008–2033.
| 55–70, 1 year | 55–70, 2 year | 55–75, 4 year | |
|---|---|---|---|
| PSA tests | 453 740 | 243 387 | 163 545 |
| Biopsies | 24 488 | 23 759 | 29 954 |
| Cancers detected | 5850 | 5709 | 6981 |
| Active surveillance | 1714 | 1614 | 1942 |
| Radical prostatectomy | 1792 | 1779 | 2214 |
| Radiation therapy | 2099 | 2065 | 2608 |
| Palliative therapy | 245 | 251 | 217 |
| Palliative therapy after primary treatment | 218 | 246 | 277 |
| Costs screening (kEuro) | 10 890 (14%) | 5841 (8%) | 3925 (5%) |
| Costs biopsies and treatment | |||
| Clinical | 13 032 (17%) | 13 695 (19%) | 9889 (12%) |
| Relevant | 22 758 (30%) | 22 476 (32%) | 27 412 (33%) |
| Overdetected | 29 446 (39%) | 28 524 (40%) | 42 165 (51%) |
| Total costs (kEuro) | 76 126 | 70 536 | 83 391 |
Abbreviation: PSA=prostate-specific antigen. Three screening scenarios are shown: screening for the ages 55–70 with a 1-year interval and a 2-year interval and screening for the ages 55–75 with a 4-year interval. The attendance is 100% in all scenarios.